Vineet Laboratories Ltd
Pharmaceuticals | Small Cap
Health Score : 4.70Vineet Laboratories Ltd, operating in the Pharmaceuticals & Biotechnology sector, demonstrates a mixed financial performance. The company shows notable strength in solvency and growth, indicating a stable capital structure and significant expansion in key areas like revenue and assets. However, it faces challenges in profitability, efficiency, and coverage, which could impact its long-term sustainability. While the company has managed to grow its assets and revenue substantially, its profitability margins remain thin. The company's ability to service its debt is also a concern. These factors suggest a need for strategic adjustments to enhance overall financial health and competitive positioning. The company's heavy reliance on debt financing and low-profit margins highlight potential vulnerabilities. Continued focus on operational improvements and strategic investments is crucial for sustainable growth and value creation.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio7.00
- Financial Ratio5.00
- Profitability Ratio2.50
- Efficiency Ratio3.50
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio0.00
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Health Score : 4.70Vineet Laboratories Ltd, operating in the Pharmaceuticals & Biotechnology sector, demonstrates a mixed financial performance. The company shows notable strength in solvency and growth, indicating a stable capital structure and significant expansion in key areas like revenue and assets. However, it faces challenges in profitability, efficiency, and coverage, which could impact its long-term sustainability. While the company has managed to grow its assets and revenue substantially, its profitability margins remain thin. The company's ability to service its debt is also a concern. These factors suggest a need for strategic adjustments to enhance overall financial health and competitive positioning. The company's heavy reliance on debt financing and low-profit margins highlight potential vulnerabilities. Continued focus on operational improvements and strategic investments is crucial for sustainable growth and value creation.
Overall Valuation Score
P/E RATIO (TTM)
-1.75
Industry Median
19.41
Small Cap Median
18.08
P/E RATIO
-1.45
P/B RATIO
2.06
Industry Median
1.98
Small Cap Median
2.03
P/S RATIO
0.39
Industry Median
2.06
Small Cap Median
1.64
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-2.32
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹31.7 as on Feb 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth Score : 7.00The company's growth shows a varied performance. Revenue has grown substantially. Asset growth is also strong, suggesting significant investments and expansion. However, earnings per share growth is low, indicating that profitability has not kept pace with revenue and asset growth. While the company is expanding, measures to improve profitability and efficiency are necessary to translate growth into enhanced shareholder value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateAverage| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | N/A | -21.4 | 10.99 | -28.77 | -50.33 |
| Operating Profit Growth Rate | N/A | 62.5 | -38.46 | -12.5 | -328.57 |
| Earnings Per Share (EPS) Growth | -904.17 | 273.06 | -81.11 | -17.65 | -2055.36 |
| Asset Growth Rate | N/A | 22.02 | -12.78 | 0.86 | -18.8 |
| Net Income Growth Rate | N/A | 250 | -85.71 | 0 | -2100 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 5.00The company's financial metrics present a mixed performance. While capital expenditures are well-managed, adjusted earnings per share, cash earnings per share, and book value per share are below expectations. The company distributed dividends, which can be seen as a positive sign for investors, but it impacts the cash flow of the company. Focusing on improving earnings and asset value is crucial to enhance overall financial health and investor confidence.
Adjusted Earnings Per Share (Adjusted EPS)Poor
Cash Earnings Per Share (Cash EPS)WeakBook Value Per ShareWeakDividend Per Share (DPS)AverageCapital Expenditures (CapEx)Excellent| Financial Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.22 | 7.78 | 1.11 | 1.11 | -22.22 |
| Cash Earnings Per Share (Cash EPS) | 4.44 | 10 | 3.33 | 4.44 | -20 |
| Book Value Per Share | 28.89 | 36.67 | 36.67 | 38.89 | 15.56 |
| Dividend Per Share (DPS) | 0 | 1.01 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0 | 0 | 7.6 | 2.8 | 1.1 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 2.50The company's profitability shows a poor performance. Gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin are below expectations. These low margins indicate that the company is facing challenges in converting revenue into profit. Enhancing operational efficiency, controlling costs, and optimizing pricing strategies are crucial to improve profitability and ensure long-term sustainability.
Gross Profit MarginPoorReturn on Capital Employed (ROCE)WeakReturn on Equity (ROE)PoorReturn on Assets (ROA)PoorOperating MarginPoorNet MarginPoor| Profitability Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Gross Profit Margin | 2.47 | 5.76 | 2.83 | 2.65 | -24 |
| Return on Capital Employed (ROCE) | 16.88 | 17.82 | 7.26 | 6.03 | -29.42 |
| Return on Equity (ROE) | 7.69 | 21.21 | 3.03 | 2.86 | -142.86 |
| Return on Assets (ROA) | 7.34 | 9.77 | 6.9 | 5.98 | -16.84 |
| Operating Margin | 3.29 | 6.81 | 3.77 | 4.64 | -21.33 |
| Net Margin | 0.82 | 3.66 | 0.47 | 0.66 | -26.67 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 3.50The efficiency of Vineet Laboratories Ltd presents a mixed picture. The inventory turnover is low, and the number of days inventory is held is high. Receivables turnover is slow, resulting in a longer collection period. These inefficiencies in working capital management can tie up resources and increase operational costs. Improving inventory and receivables management could significantly enhance the company's overall efficiency and financial performance.
Inventory Turnover RatioPoorReceivables Turnover RatioAverageDays Sales in Inventory RatioPoorReceivable DaysWeak| Efficiency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 12.15 | 9.1 | 7.85 | 5.59 | 3 |
| Inventory Turnover Ratio | 11.85 | 4.29 | 4.6 | 3.07 | 1.88 |
| Receivables Turnover Ratio | 11.3 | 4.84 | 5.97 | 4.51 | 3.33 |
| Days Sales in Inventory Ratio | 30.8 | 85.08 | 79.35 | 118.89 | 194.15 |
| Receivable Days | 32.3 | 75.41 | 61.14 | 80.93 | 109.61 |
| Capital Turnover Ratio | 5.86 | 3.09 | 3.08 | 1.82 | 1.3 |
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Coverage Score : 2.00The company's coverage ratio indicates a weak position. The ability to cover interest expenses is below the threshold, suggesting a significant risk in meeting debt obligations. Low interest coverage can strain financial resources and increase vulnerability to economic downturns. Improving profitability or reducing debt could enhance the company's interest coverage and financial stability.
Interest Coverage RatioPoorEquity Dividend Coverage RatioAverage| Coverage Ratios | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Interest Coverage Ratio | N/A | 2.33 | 5.5 | 1.67 | 1 | -4.25 |
| Equity Dividend Coverage Ratio | N/A | N/A | 7.14 | N/A | N/A | N/A |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00The company's solvency displays a mixed outlook. The company maintains a low debt relative to its equity, suggesting a conservative capital structure. However, its ability to cover interest expenses is average, indicating a moderate risk in meeting debt obligations. While the debt levels are well-managed, the interest coverage could be stronger to ensure better financial stability.
Debt RatioExcellentDebt to Equity RatioExcellentInterest Coverage RatioAverage| Solvency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debt Ratio | 0.12 | 0.05 | 0.13 | 0.1 | 0.21 |
| Debt to Equity Ratio | 0.14 | 0.05 | 0.15 | 0.11 | 0.27 |
| Equity Ratio | 0.88 | 0.95 | 0.87 | 0.9 | 0.79 |
| Debt To Asset Ratio | 0.03 | 0.01 | 0.04 | 0.03 | 0.04 |
Debt Ratio
Debt to Equity Ratio
Interest Coverage Ratio
Liquidity Score : 0.00The company's liquidity position cannot be determined due to insufficient data. A comprehensive assessment of the company's ability to meet its short-term obligations is not possible without the values for the metrics that make up the liquidity ratio.
Current RatioAverageQuick RatioAverageCash RatioAverage| Liquidity Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Current Ratio | 1.13 | 1.13 | 1.15 | 1.15 | 0.9 |
| Quick Ratio | 0.62 | 0.69 | 0.56 | 0.52 | 0.25 |
| Cash Ratio | 0.03 | 0.18 | 0.01 | 0 | 0.01 |
| Operating Cash Flow Ratio | 0.34 | 0.08 | -0.13 | -0.09 | 0.14 |
Current Ratio
Quick Ratio
Cash Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vineet Laboratories Ltd | 4.70 | -1.45 | Neutral | -16.00 | -21.90 | -20.00 |
Weak ManagementThe management effectiveness of Vineet Laboratories Ltd. appears weak based on the available data. The company exhibits declining sales and profit growth, coupled with inconsistent profitability. Its capital efficiency is poor, as indicated by low ROCE and ROE. Furthermore, the company's financial health is concerning, with increasing debt levels. These factors collectively suggest significant challenges in the company's financial management and operational performance.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 36.07% | Confidence and alignment with shareholders |
| CONS | Sales Growth (3Y) | -15% | Declining revenue expansion |
| Profit Growth (3Y) | -24% | Weak profit growth | |
| ROCE | 7.16% | Capital utilization is low |
Financial Performance & GrowthPoorCapital Efficiency & ReturnsWeakFinancial Health & PrudencePoorStrategic & Operational IndicatorsAverageFinancial Performance & Growth
Vineet Laboratories demonstrates concerning trends in financial performance and growth. The compounded sales growth over the past three years is -15%, and the TTM sales growth is -45%, suggesting a significant contraction in revenue. Similarly, the compounded profit growth over three years is -24%, with a TTM profit growth of -167%, indicating a sharp decline in profitability. Quarterly results reveal inconsistent sales and profit figures, with significant fluctuations. Operating Profit Margin (OPM) has also been volatile with negative values in recent quarters, highlighting operational inefficiencies. Overall, the company's financial performance indicates substantial challenges in achieving sustainable growth and profitability.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Sales Growth (%) | N/A | -21.51% | 11.09% | -29.06% |
| OPM (%) | 3% | 7% | 4% | 5% |
Capital Efficiency & Returns
The capital efficiency and returns of Vineet Laboratories are notably weak. The current ROCE is 7.16%. The Return on Equity (ROE) is low at 3%. The Cash Conversion Cycle has deteriorated, increasing to 131 days in March 2024 from 23 days in March 2021, indicating inefficiencies in working capital management. These metrics collectively suggest that the company is struggling to generate adequate returns from its capital investments and manage its working capital effectively.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| ROCE (%) | 34% | 23% | 9% | 7% |
| Cash Conversion Cycle (Days) | 23 | 17 | 84 | 131 |
Financial Health & Prudence
Vineet Laboratories exhibits concerning financial health and prudence. Borrowings have increased significantly, rising from ₹12 Cr in March 2021 to ₹44 Cr in March 2024. This increased leverage is reflected in the rising debt levels. The company's ability to cover interest expenses appears strained. The company has not consistently shared profits, with no dividend payout in recent years. This combination of factors indicates potential financial stress and increased risk associated with the company's capital structure.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Borrowings (₹ Cr) | 12 | 27 | 31 | 44 |
Strategic & Operational Indicators
The strategic and operational indicators for Vineet Laboratories present a mixed picture. The working capital management shows increasing challenges. Debtor Days have increased to 77 in Mar 2024. Inventory Days have increased to 158 in Mar 2024. Payables Days increased to 103 in Mar 2024.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Debtor Days | 64 | 69 | 60 | 77 |
| Inventory Days | 73 | 109 | 98 | 158 |
| Payable Days | 114 | 161 | 74 | 103 |
Weak RiskThe risk assessment for Vineet Laboratories is red, indicating high risk. The company has a negative profit, declining sales, and increasing debt, all of which elevate the risk profile. The inconsistency in profitability, inefficient working capital management, and high leverage levels raise concerns about its long-term sustainability. These factors contribute to an overall high-risk assessment.
Off-balance sheet exposure quantificationAverageContingent liability evaluationAverageAccounting quality red flagsAverageOff-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Accounting quality red flags
There is no specific data available on accounting quality red flags.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe